Initial Reaction and Epinephrine Response
The first phase begins the severity timeline this simulator tracks.
- 1st line: Epinephrine (IM injection, anterolateral thigh)
- <1 h: Onset to peak (typical first-phase timing)
- 5–15 min: Redosing interval (if inadequate response)
- 1–20%: Biphasic incidence (wide reported range)
Acute phase overview
Short placeholder describing the acute anaphylactic reaction and initial treatment.
Placeholder highlight on early epinephrine timing.
The Symptom-Free Quiet Interval Window
Placeholder sentence on the asymptomatic gap after initial improvement.
- 1–8 h: Typical interval (most common reported range)
- 72 h: Max reported gap (outer bound for monitoring)
- Absent: Symptom status (placeholder clinical state)
- High: False reassurance risk (placeholder caution note)
Why symptoms disappear
Placeholder text on transient mediator clearance during the quiet interval.
Second-Phase Mediator Resurgence Risk
Placeholder sentence on late-phase mediator release mechanisms.
- Cytokines: Late mediators (placeholder mediator class)
- Variable: Severity vs phase 1 (can be milder or worse)
- Severity: Risk factor (higher initial severity raises risk)
- Delayed epi: Risk factor (placeholder secondary factor)
Resurgence mechanism
Placeholder text describing late-phase inflammatory mediator resurgence.
Placeholder highlight on severity-linked recurrence risk.
Recurrence Timing Across the 1–72 Hour Range
Placeholder sentence on the broad reported timing distribution.
- 1–72 h: Reported range (literature-wide window)
- 6–12 h: Most common (placeholder typical cluster)
- ~10 h: Median estimate (placeholder summary figure)
- >48 h: Rare late cases (placeholder tail cases)
Timing distribution
Placeholder text on why recurrence timing varies so widely between patients.
Observation Period Decision-Making
Placeholder sentence on choosing a safe observation duration.
- 4–6 h: Standard observation (placeholder default duration)
- 24 h: Extended observation (placeholder high-risk duration)
- Severity: Decision driver (placeholder key factor)
- Symptom-free: Discharge criteria (placeholder criterion)
Balancing risk and resources
Placeholder text on clinical decision-making for discharge timing.
Placeholder highlight on individualized observation planning.